Table 4 Summary of progression-free survival (PFS).

From: Safety and tolerability of asunercept plus standard radiotherapy/temozolomide in Asian patients with newly-diagnosed glioblastoma: a phase I study

 

Cohort 1, 200 mg/week (n = 3)

Cohort 2, 400 mg/week (n = 7)

Total (N = 10)

Median PFSa, months (95% CI)

2.37 (2.33, 6.01)

NE (2.30, NE)

5.01 (2.30, NE)

Events, n

3

3

6

Progression-free rates, % (95% CI)

3 months

33.3 (0.9, 77.4)

71.4 (25.8, 92.0)

60.0 (25.3, 82.7)

6 months

33.3 (0.9, 77.4)

57.1 (17.2, 83.7)

50.0 (18.4, 75.3)

9 months

0.0

57.1 (17.2, 83.7)

40.0 (12.3, 67.0)

12 months

0.0

57.1 (17.2, 83.7)

40.0 (12.3, 67.0)

PFS-6, % (95% CI)b

33.3 [0.8, 90.6]

57.1 [18.4, 90.1]

50.0 [18.7, 81.3]

Disease progression within 6 months, n

2

3

5

  1. NE not evaluable (four patients in Cohort 2 had not experienced progression at the time of cut-off).
  2. aKaplan–Meier methodology is used to estimate median time and its 95% confidence interval (CI).
  3. bExact 95% CI is calculated according to Clopper–Pearson.
Back to article page